Exelixis Inc Liabilities Assumed
Exelixis Inc (EXEL) reported Liabilities Assumed of $0 for the 12-month period ending 2026-01-02, per its 10-K filed 2026-02-10.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:LiabilitiesAssumed1 · last filed 2026-02-10
- Exelixis Inc liabilities assumed for the quarter ending 2022-12-30 was $0.00.
- Exelixis Inc liabilities assumed for the quarter ending 2022-09-30 was $0.00.
- Exelixis Inc liabilities assumed for the quarter ending 2021-12-31 was -$5.00M.
- Exelixis Inc liabilities assumed for the quarter ending 2021-10-01 was $0.00.
- Exelixis Inc liabilities assumed for fiscal 2026 was $0.00, a 100.00% decline from fiscal 2025.
- Exelixis Inc liabilities assumed for fiscal 2025 was $19.50M, a 200.00% increase from fiscal 2023.
- Exelixis Inc liabilities assumed for fiscal 2023 was $6.50M, a 1200.00% increase from fiscal 2022.
- Exelixis Inc liabilities assumed for fiscal 2022 was $500.00K, a 87.50% decline from fiscal 2021.
| Period end | Liabilities Assumed 3 month | Liabilities Assumed 6 month | Liabilities Assumed 9 month | Liabilities Assumed 12 month |
|---|---|---|---|---|
| 2026-01-02 | $0.00 10-K · filed 2026-02-10 | |||
| 2025-01-03 | $19.50M 10-K · filed 2026-02-10 | |||
| 2023-12-29 | $6.50M 10-K · filed 2026-02-10 | |||
| 2022-12-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $0.00 derived: sum of 2 quarters · filed 2025-02-11 | $500.00K 10-K · filed 2025-02-11 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $500.00K 10-Q · filed 2022-11-01 | ||
| 2022-07-01 | $500.00K 10-Q · filed 2022-08-09 | |||
| 2021-12-31 | -$5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | -$5.00M derived: sum of 2 quarters · filed 2022-11-01 | $4.00M 10-K · filed 2022-02-18 | |
| 2021-10-01 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $9.00M 10-Q · filed 2022-11-01 | ||
| 2021-07-02 | $9.00M 10-Q · filed 2022-08-09 | |||
| 2021-01-01 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $0.00 derived: sum of 2 quarters · filed 2022-02-18 | $0.00 10-K · filed 2022-02-18 | |
| 2020-10-02 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $0.00 10-Q · filed 2021-11-02 | ||
| 2020-07-03 | $0.00 10-Q · filed 2021-08-05 | |||
| 2020-01-03 | $0.00 10-K · filed 2022-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |